Morten Beck Jorgensen

Managing Director, Financial Investments at Novo Holding A/S

Morten Beck Jorgensen

Morten Beck Jorgensen

Managing Director, Financial Investments at Novo Holding A/S

Overview
RelSci Relationships

244

Relationships
RelSci Relationships are individuals Morten Beck Jorgensen likely has professional access to. A relationship does not necessarily indicate a personal connection.

Former Chief Financial Officer at Novo Holding A/S

Relationship likelihood: Strong

Partner, Seed Investments at Novo Holding A/S

Relationship likelihood: Strong

Professional at Novozymes Biotech, Inc.

Relationship likelihood: Strong

Head of People & Organisation People & Organisaton at Novo Holding A/S

Relationship likelihood: Strong

Managing Partner NOVO Ventures at Novo Holding A/S

Relationship likelihood: Strong

Venture Partner NOVO Ventures at Novo Holding A/S

Relationship likelihood: Strong

Senior Partner NOVO Ventures at Novo Holding A/S

Relationship likelihood: Strong

Senior Director, Financial Investments at Novo Holding A/S

Relationship likelihood: Strong

Operations Manager NOVO Ventures at Novo Holding A/S

Relationship likelihood: Strong

Chief Financial Officer, Finance & Operations at Novo Holding A/S

Relationship likelihood: Strong

Paths to Morten Beck Jorgensen
Potential Connections via
Relationship Science
You
Morten Beck Jorgensen
Managing Director, Financial Investments at Novo Holding A/S
Education
Class of 1997

Aarhus University is a school in Aarhus.

MS Finance

Aarhus School of Business is a school in Aarhus.

Career History
Managing Director, Financial Investments
2005 - Current

Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation’s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark.

Senior Investment Director
Tenure Unconfirmed

Novo is an active, long-term manager which aims to support sustainable partnerships through the advancement of life sciences, investing more than half of their capital in North American companies and the rest in Denmark and Europe. The firm invests across technologies, products and financial stages, including providing funds for embryonic start-ups in extraordinary situations.Novo makes typical equity investments of 1-15 million euros, focusing on investee companies with significant profit and growth potential within the following areas: products that diagnose, control, treat and prevent disease; biotechnology development and applications; instruments and medical devices; improvement of food, nutrition and health for humans and animals and development of sustainable solutions for the environment.The firm typically takes a minority position in their investee companies, seeking to provide value-adding support in areas such as intellectual property rights, scientific evaluation, strategic business development, licensing and collaborations and financing strategies through their extensive network and active participation on the board of directors. Their typical exit strategies include IPOs, trade sales and mergers.The financial investments of Novo A/S comprise a portfolio of well-diversified assets, including liquid and listed equities, Danish government and mortgage bonds and high-yielding credit and emerging markets bonds. The firm seeks to spread risk by diversifying the Novo Nordisk Foundation's assets and creating a pool of liquid reserves which can be used to support Novo Group companies.

Assistant Treasurer
2001 - 2005

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following business segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Other Affiliations

Morten Beck Jorgensen is affiliated with Novo Holding A/S, Novo Ventures, Novo Nordisk A/S, Nordea Markets